Treatment of Special Populations with Hepatitis C Virus Infection: Chronic Kidney Disease.
10.3904/kjm.2015.88.6.647
- Author:
Woo Jin CHUNG
1
Author Information
1. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. chung50@dsmc.or.kr
- Publication Type:Review
- Keywords:
Hepatitis C;
Renal insufficiency, Chronic;
Renal dialysis
- MeSH:
Antiviral Agents;
Hepacivirus*;
Hepatitis C;
Humans;
Interferons;
Kidney Failure, Chronic;
Liver;
Mortality;
Prognosis;
Renal Dialysis;
Renal Insufficiency, Chronic*;
Ribavirin
- From:Korean Journal of Medicine
2015;88(6):647-650
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hepatitis C virus (HCV) infection is prevalent in patients with chronic kidney disease, especially those on hemodialysis. Chronic HCV infection in patients with end-stage renal disease is associated with increased morbidity and mortality in the pre- and post-kidney transplant periods. Increased mortality is associated with liver complications and an elevated cardiovascular risk in HCV-infected patients on hemodialysis. Antiviral treatment may improve the prognosis of patients with HCV, and standard interferon remains the cornerstone of treatment. Direct-acting antiviral agents (DAA) are a potential new treatment modality for chronic HCV infection. Whatever DAA combination is administered, the use of ribavirin is still problematic in this population and this might affect the virological outcomes of some anti-HCV therapies.
